KYG108301006 - Common Stock
FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global...
We're starting Wednesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on this morning!
BeyondSpring regains compliance with Nasdaq minimum bid price requirement, with the stock trading at $1.09 on Monday.
BeyondSpring (BYSI) is facing non-compliance with Nasdaq as it failed to file its Form 6-K.
NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical...
BeyondSpring (BYSI) received a notification from Nasdaq regarding its non-compliance with the minimum closing bid price requirement; no immediate delisting.
NEW YORK, Dec. 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical...
NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- SEED Therapeutics Inc. (“SEED”), a biotech company focused on harnessing and engineering Molecular Glues for...
Former Eisai Board Member, Former World Bank General Counsel, and Lecturer at Harvard and Yale Law Schools, Brings Five Decades of Experience in Global...
It's time to start off the week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning!
NEW YORK, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical...
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage...
NEW YORK, Sept. 07, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage...
NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a global clinical-stage biopharmaceutical...
- SEED Therapeutics, a BeyondSpring Subsidiary, Achieved Milestones on the Eli Lilly Collaboration - BeyondSpring Completed Enrollment of Three...
NEW YORK, April 18, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical-stage global...
Clinical stage global biopharmaceutical company focused on developing innovative cancer therapies, BeyondSpring (BYSI) received a written notification from Nasdaq that the company...
NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (Nasdaq: BYSI), a clinical stage global biopharmaceutical...